
## Nutthapoom Pathomthongtaweechai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9403400/publications.pdf

Version: 2024-02-01



Νυττηαροομ

#	Article	IF	CITATIONS
1	Tight junctions: from molecules to gastrointestinal diseases. Tissue Barriers, 2023, 11, .	1.6	8
2	Establishment of Intestinal Epithelial Cell Monolayers and Their Use in Calcium Switch Assay for Assessment of Intestinal Tight Junction Assembly. Methods in Molecular Biology, 2021, 2367, 273-290.	0.4	6
3	Potential Applications of Chitosan-Based Nanomaterials to Surpass the Gastrointestinal Physiological Obstacles and Enhance the Intestinal Drug Absorption. Pharmaceutics, 2021, 13, 887.	2.0	28
4	AGE/RAGE signaling-mediated endoplasmic reticulum stress and future prospects in non-coding RNA therapeutics for diabetic nephropathy. Biomedicine and Pharmacotherapy, 2020, 131, 110655.	2.5	38
5	Novel Potential Application of Chitosan Oligosaccharide for Attenuation of Renal Cyst Growth in the Treatment of Polycystic Kidney Disease. Molecules, 2020, 25, 5589.	1.7	7
6	Novel Effect of Chitooligosaccharide on Cyst Growth Retardation in an <i>in vitro</i> Cyst Model of Polycystic Kidney Disease. FASEB Journal, 2020, 34, 1-1.	0.2	0
7	Inhibition of cAMP-Activated Intestinal Chloride Secretion by Diclofenac: Cellular Mechanism and Potential Application in Cholera. PLoS Neglected Tropical Diseases, 2014, 8, e3119.	1.3	15
8	Pranlukast inhibits renal epithelial cyst progression via activation of AMP-activated protein kinase. European Journal of Pharmacology, 2014, 724, 67-76.	1.7	10
9	Antiâ€esthmatic drug pranlukast attenuates cyst progression in an MDCK cyst model (690.4). FASEB Journal, 2014, 28, 690.4.	0.2	Ο
10	Inhibition of renal cyst progression by montelukast: an in vitro study in MDCK cells. FASEB Journal, 2013, 27, 912.1.	0.2	0